PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Douglas J. Hilton et al. Group: 1643

Serial No.: 08/962,560 Docket:

10976

Filed:

October 31, 1997

OCCODE: 31, 1997

For: THERAPEUTIC AND DIAGNOSTIC AGENTS

Assistant Commissioner for Patents Washington, D.C. 20231

July 13, 1998



VERIFICATION UNDER 37 C.F.R. § 1.821(f)

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Frank S. DiGiglio Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER 400 Garden City Plaza Garden City, New York 11530 (516) 742-4343 FSD/XZ:mg1

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on July 13, 1998.


Dated: July 13, 1998

Frank S. DiGigl W

Application	n No.: _	
CUT ABOUT		

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

1,825(b) or 1,825(d).

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or